←
Al Garfall410 posts
Al Garfall avatar

Al Garfall

@AlGarfall

Oncologist @PennMedicine @PennCancer specializing in multiple myeloma and cellular immunotherapy.

◷ Joined July 2014▧ 4 Photos and videos
Rahul Banerjee, MD, FACP avatar
⟳ Al Garfall retweeted
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·Oct 29

Update: We did it!! For 🇺🇸 pts with myeloma, Medicare coverage for transplant is safe and sound. No more exclusion of Stage I #MMsm or CKD! Thanks to all who submitted comments; 👏 @AJPortuguese for govt testimony with help from @ASTCT and @ASH_hematology. Advocacy works!

Post attachment

🚨🚨🚨 Help preserve transplants for 🇺🇸 pts with myeloma! All patients, MDs, RNs, & anyone who knows transplant is good option for Medicare beneficiaries: Please comment on CMS proposed memo by Aug 29th. Link 👇🏼 This is a big deal. ASCT no longer covered for ISS stage I 🤯

Post attachment
Stanford University avatar
⟳ Al Garfall retweeted
Stanford University@Stanford·Oct 5

The most important briefings of the day. Karl Deisseroth, professor of bioengineering and of psychiatry and behavioral sciences, shares the news of his Nobel Prize with his kids.

0:45
Tanya Bondar avatar
⟳ Al Garfall retweeted
Tanya Bondar@_TanyaBondar_·Sep 25

Free to read via the Myeloma Collection link during #IMS26 (though Sunday): aacrjournals.org/bloodcancer… @AlGarfall

Read this research brief by #IMS26 speakers Rahul Banerjee, Doris Hansen, and Surbhi Sidana, “Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.” aacrjournals.org/bloodcancer… @rahulbanerjeeMD @SurbhiSidanaMD

Post attachment
Raj Chakraborty avatar
⟳ Al Garfall retweeted
Raj Chakraborty@rajshekharucms·Sep 24

Incredible 2-year PFS with Ramantamig in a ~95% CD38-refractory and 100% triple-class exposed population! These results are substantially superior compared to single-agent BCMA BsAbs and BCMA or GPRC5D CAR Ts in similar population. Based on these results, its plausible that we will see a near-flat PFS curve with Ram in Trilogy-5! #IMS26 @AlGarfall @MileHighMyeloma

Post attachment
Raj Chakraborty avatar
⟳ Al Garfall retweeted
Raj Chakraborty@rajshekharucms·Sep 15

Such an exciting milestone for another groundbreaking RCT in newly diagnosed #myeloma from @CoMMitTrials testing time-limited BsAb therapy to improve outcomes in MRD-positive and de-escalating ASCT in MRD-negative patients after Quad induction! Grateful for the small role we got to play in it @columbiacancer!

This paradigm-challenging trial is 💯 accrued! Congratulations to the sites, investigators, staff and our gratitude to patients. @bhemato @ldandersonjr @nsc_natalie @SusanBal9 @CBCIDocs @rajshekharucms @huntsmanMM @RahulBanerjeeMD @DholariaMD @MMBaljevicMD @End_myeloma

Post attachment
Hira Mian avatar
⟳ Al Garfall retweeted
Hira Mian@HiraSMian·Sep 15

Anticd38 are absolutely pivotal in myeloma, the question of how long to use it still remains open, there likely is a sweet spot, glad our trial @CDNCancerTrials @AnnetteHay1 will try to address this @MyelomaCanada

The oncology blockbuster race in 2025: 💊 Keytruda leads at $31.6B, followed by Darzalex at an impressive $14.35B and Opdivo at $10B—remarkably, a #MultipleMyeloma therapy now ranks #2 among the world’s top-selling oncology drugs! 🌎🔥 #Myeloma #Oncology #CancerResearch

Post attachment
Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 avatar
⟳ Al Garfall retweeted
Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉@BLLPHD·Aug 27

🚨NEW @BloodPortfolio Why do some CLL-derived CAR T-cell products fail even when they still produce inflammatory cytokines? @jh_noll et al (link in reply) identifies immunosenescence, not exhaustion alone. -Senescence and Senescence Associate Secretory Phenotype (SASP) programs were detectable before infusion, intensified during manufacturing in susceptible products, and tracked with weak in vivo CAR T-cell expansion and inferior survival. - Repeated CD19 stimulation exposed a proliferative ceiling, while p53-high products lost cytotoxic reserve. Poor response was also associated with costimulatory loss and reduced TCR diversity. - Ibrutinib attenuated senescence-associated features and SASP output and improved proliferative fitness. The broader message: starting T-cell fitness is measurable and potentially modifiable. #immunology #immunotherapy #immunosenescence #TCell #CARTCell #CLL

Post attachment
Philadelphia Phillies avatar
⟳ Al Garfall retweeted
Philadelphia Phillies@Phillies·Aug 23

WALK-OFF SCHWARBOMB OVER THE BATTER'S EYE!!!!!!

0:32
Hira Mian avatar
⟳ Al Garfall retweeted
Hira Mian@HiraSMian·Aug 4

De-escalation in MM: Tough questions—but we now have the tools and drugs to do this in select pts. Here we review existing evidence and offer practical guidance for designing the next wave of de-escalation trials @End_myeloma @Mohty_EBMT @AlGarfall @VincentRK

Post attachment